Carl Zeiss Meditec
€31.30Change from previous close: +0.32%Absolute change: +€0.10
At a glance
- Revenue growth
- +7.82%
- FY to Sep 2025 vs FY to Sep 2024
- Net income growth
- −20.99%
- FY to Sep 2025 vs FY to Sep 2024
- Net margin
- 6.3%
- FY to Sep 2024: 8.7%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q3 2025 | Q1 2025 |
|---|---|---|
| Total assets | 3,403 | 3,474 |
| Current assets | 1,272 | 1,284 |
| Cash and equivalents | 27.3 | 26.6 |
| Short-term investments | — | 24.9 |
| Inventory | 497 | 551 |
| Net property, plant and equipment | 343 | 356 |
| Goodwill | 970 | 992 |
| Other intangible assets | 663 | 696 |
| Long-term investments | 28.9 | 22.4 |
| Current liabilities | 544 | 628 |
| Accounts payable | 194 | 189 |
| Total debt | 132 | 147 |
| Total liabilities | 1,276 | 1,384 |
| Total equity (incl. minority) | 2,128 | 2,090 |
| Retained earnings | 1,575 | 1,495 |
| Minority interest | 11.2 | 14.1 |